Artificial Intelligence Is Future Of Postmarketing Surveillance, US FDA’s Marks Says
Executive Summary
CBER director’s vision for a national safety surveillance system includes use of AI and natural language processing to enable near-real time signal detection from adverse event reports.
You may also be interested in...
Cell Therapy Manufacturing Hurdles Could Be Solved Through AI; ‘Great Advancements’ In Next 10 Years
Artificial intelligence could be the solution to some of the process challenges with cell therapies; CBER Director Marks also suggests AI to identify safety issues with a particular vector.
FDA’s CDER Is Fostering Use Of Artificial Intelligence In Drug Development
Center for Drug Evaluation and Research plans to issue a request for information this year to engage stakeholders on issues related to AI and machine learning. It received 175 AI/ML submissions in 2022, up from 14 in 2020.
Califf: FDA Vaccine Safety Oversight Would Be Enhanced By Federal Public Health Data Authority
US FDA continues to push for new federal funding and authorities to improve vaccine safety surveillance.